View
2
Download
0
Category
Preview:
Citation preview
10/12/2018
1
Thromboembolism Q & ACases & Controversies
TRACY MINICHIELLO, MDPROFESSOR OF MEDICINECHIEF, ANTICOAGULATION AND THROMBOSIS SERVICESAN FRANCISCO VA MEDICAL CENTER
Central Venous Access Device-Related Upper Extremity DVT
A 62 yo man is admitted with respiratory failure due to community acquired pneumonia. He is hypotensive on admission and is intubated. He requires central access for pressor support . On HD #4 his RUE is swollen and U/S shows DVT in his axillary and brachial veins. How do you manage this DVT?
A) remove the line, start full dose anticoagulation and place new central line in contralateral arm
B) start anticoagulation, do not remove the central line as central access is still needed
10/12/2018
2
10/12/2018
3
At least 7 days of anticoagulation prior to catheter removal to reduce risk of TEConsider on case be case basis
IVC Filters
A 50 year old man is on warfarin for recurrent VTE. His last VTE event was 8 years ago. He is well controlled with TTR of 85%. H presents with sudden onset LLE swelling and pain and he says it “feels like a DVT”. D-dimer is 1500. Ultrasound shows acute expansile DVT in the distal femoral vein, new since prior U/S one year ago. He is transitioned to LMWH. He is told he needs an IVC filter to prevent PE. a) Yes,it will decrease his risk of PEb) No, it will increase his risk of DVTc) All of the above
10/12/2018
4
VTE Recurrence on Anticoagulation
10/12/2018
5
VTE Recurrence on Anticoagulation
Behnood Bikdeli et al. JACC 2017;70:1587-1597
2017 American College of Cardiology Foundation
10/12/2018
6
IVC Filters
A 50 year old man is on warfarin for recurrent VTE. His last VTE event was 8 years ago. He is well controlled with TTR of 85%. H presents with sudden onset LLE swelling and pain and he says it “feels like a DVY”. D-dimer is 1500. Ultrasound shows acute expansile DVT in the distal femoral vein, new since prior U/S one year ago. He is transitioned to LMWH. He is told he needs an IVC filter to prevent PE. a) Yes,it will decrease his risk of PEb) No, it will increase his risk of DVTc) All of the above
Incidental PE
A 77 yo man is 2 weeks s/p laproscopic nephrectomy for renal cell CA. He received LMWH for 5 days post op but this was discontinued when he developed melena. An EGD showed a peptic ulcer. He has a staging CT which shows no disease but shows a RUL subsegmentalpulmonary artery filling defect. Do you anticoagulated this patient?a) No, that did not go well last timeb) Yes, it is a PEc) Not again. Didn’t we just talk about this?
10/12/2018
7
Should I Treat This Isolated Subsegemental PE?
Kearon et al. Chest. 2016;149(2):315-352.
Incidental PE in Cancer
10/12/2018
8
Should I Treat This Isolated Subsegemental PE?
Kearon et al. Chest. 2016;149(2):315-352.
1st IS IT REAL? good scan, multi defects, central, sx, + d-dimer
2nd Consider risk of recurrence if not treated Hospitalized, reduced mobility, CA, no reversible risk factor
3rd Consider bleeding risk 4th Make an individualized plan High risk recurrence-treat Low cardiopulm reserve or no alternative etiology of sx-
consider treating Low risk recurrence or high bleeding risk- get U/S lower extrem
(& upper if CVC). IF + DVTtreat If NO DVTserial u/s
Incidental PE in CancerLOCATION RECOMMENDATIONProximal DVT or main, lobar segmental or multiple subsegmental PE
AC for at least 6 months
ISSPE with proximal DVT AC for at least 6 months
ISSPE with distal DVT or no DVT
Case be case;consider risk of bleeding/ recurrent thrombosis, patient preference. If no anticoagulation serial U/S to detect thrombus
10/12/2018
9
Incidental PE
A 77 yo man is 2 weeks s/p laproscopic nephrectomy for renal cell CA. He received LMWH for 5 days post op but this was discontinued when he developed melena. An EGD showed a peptic ulcer. He has a staging CT which shows no disease but does show a RUL subsegmental pulmonary artery filling defect. Do you anticoagulated this patient?a) No, that did not go well last timeb) Yes, it is a PEc) Not again. Didn’t we just talk about this?
Calf Vein DVTA 37 year old man presents with right calf pain one week after being kicked in calf during a soccer game. On exam right calf is 2 cm> left. U/S shows DVT in the peroneal vein. What anticoagulation regimen do you recommend?1. Rivaroxaban 15 mg BID x 21 days then 20 mg daily to complete
3 months of therapy2. Prophylactic dosing of LMWH or DOAC3. No anticoagulation, return in one week for repeat ultrasound of
lower extremity.4. Um, is that a deep vein? The guy sitting next to me wants to
know but is embarrassed to ask.
10/12/2018
10
Also includes gastroc and soleus veins
Calf Vein DVT-CHEST 2016
Kearon et al. Chest. 2016;149(2):315-352.
Risk factors for extension: d-dimer +, extensive thrombosisclose to proximal veins; active cancer, prior VTE, inpatient
10/12/2018
11
Calf Vein DVT-CHEST 2016 AC Forum clinical guidance We suggest treatment of distal DVT with anticoagulation versus observation. We suggest a duration of therapy 3 months.
Streiff MB et al. J Thromb Thrombolysis. 2016;41:32-67..
Calf Vein DVT
• 1st DVT, no cancer, outpatient only• 6 weeks LMWH and GCS vs placebo and GCS• U/S at 3-7 days and 42 days• Outcome progression to proximal DVT or PE• No difference in VTE, increased risk of bleeding
Righini et al. Lancet Haematol 2016;3: e556–62
10/12/2018
12
Calf Vein DVT
A 37 year old man presents with right calf pain on week after being kicked in calf during a soccer game. On exam right calf is 2 cm> left. U/S shows DVT in the peroneal vein. What anticoagulation regimen do you recommend?1. Rivaroxaban 15 mg BID x 21 days then 20 mg daily to complete
3 months of therapy2. Prophylactic dosing of LMWH or DOAC3. No anticoagulation, return in one week for repeat ultrasound of
lower extremity.4. Um, is that a deep vein? The guy sitting next to me wants to
know and is embarrassed to ask.
Thrombocytopenia Cancer and VTE
Our 58 yo man with new PE, adenoc CA of the lung undergoing chemo has a platelet count of 65 at initiation of low molecular weight heparin but he is on a downward trajectory as expected from chemo infused last week. On HD #3 his platelet count is 42K. You: 1) Stop enoxaparin 2) Switch to half dose enoxaparin 3) Switch to prophylactic enoxaparin 4) Transfuse with platelets 4) Go into an empty room and shout “Why is it ALWAYS during my
shift???””
10/12/2018
13
HIT O points
O points
O points
O points
Thrombocytopenia Cancer and VTE
10/12/2018
14
Thrombocytopenia Cancer and VTE
Our 58 yo man with new PE, adenoc CA of the lung undergoing chemo has a platelet count of 65 at initiation of anticoagulation but he is on a downward trajectory as expected from chemo infused last week. On HD #3 his platelet count is 42K. You: 1) Stop enoxaparin 2) Switch to half dose enoxaparin 3) Switch to prophylactic enoxaparin 4) Transfuse with platelets 4) Go into an empty room and say “Why is it ALWAYS during my
shift???””
Superficial Vein Thrombosis
A 55 year old woman presents with painful swelling over anterior left thigh. On exam she has a palpable cord concerning for SVT. She has an u/s which shows thrombosis of the greater saphenous vein extending from the calf proximally and terminating 6 cm from the deep femoral vein. What do you recommend?a. Prophylactic fondaparinuxb. Prophylactic rivaroxabanc. Full dose DOAC or warfarind. NSAIDS and ice
10/12/2018
15
Superficial Vein Thrombosis –CHEST Guidelines
Factors that favor the use of AC : extensive SVT; above the knee, close to saphenofemoral junction; severe symptoms; involvement of the greater saphenous vein; history of VTE or SVT; active cancer; recent surgery
In patients with superficial vein thrombosis of the lower limb of at least 5 cm in length, we suggest the use of a prophylactic dose of fondaparinux or LMWH for 45 days over no anticoagulation (Grade 2B).
Kearon C et al. Chest. 2012
CALISTO TRIAL- fonda vs placeboPrimary outcome 1% vs 6%
Superficial Vein Thrombosis
• >400 pts symptomatic SVT riva 10 mg v fonda 2.5mg• Symptomatic above the knee SVT of at least ≥ 5 cm
length + other risk factor (>65 , male,hx VTE , cancer, autoimmune disease, non-varicose veins)
• No difference in primary efficacy outcome • After 6 weeks 7% recurrence risk in high risk patients
(v 1.2% in CALISTO)
10/12/2018
16
Full dose anticoagulationfor at LEAST 6 weeks
Superficial Vein Thrombosis
A 55 year old woman presents with painful palpable swelling over anterior left thigh. On exam she has a palpable cord concerning for SVT. She has an u/s which shows thrombosis of the greater saphenous vein extending from the calf proximally and terminating 2 cm from the deep femoral vein. What anticoagulant regimen do you recommend?a. Prophylactic fondaparinuxb. Prophylactic rivaroxabanc. Full dose DOAC or warfarind. Nsaids and ice
10/12/2018
17
DOAC for Secondary Cardiovascular Protection
55 year old with stable coronary disease with NSTEMI MI 4 years ago is on ASA 81 mg qd. His primary provider asks if he should now be started on rivaroxaban given the “new data”. You recommend:
1. Change to “low dose” rivaroxaban 5 mg bid
2. Add “very low dose” rivaroxaban 2.5 mg bid
3. Continue ASA 81 mg
COMPASS
Eikelboom JW. N Engl J Med. 2017 Oct 5;377(14):1319-1330. PMID: 28844192
RCT Riva 5 mg BID or Riva 2.5 mg BID + ASA vs ASAStable CAD or PVD1 ◦-Composite death, stroke, MI ;2◦-Major bleeding
10/12/2018
18
COMPASS
Eikelboom JW. N Engl J Med. 2017 Oct5;377(14):1319-1330. PMID: 28844192
Primary outcome 24% lower with rivaroxaban (2.5mg twice daily) plus aspirin than with aspirinalone (4.1% vs. 5.4%), but the rate of majorbleeding was higher by 70% (3.1% vs. 1.9%).
COMPASS
~ 50% reduction in stroke
Eikelboom JW. N Engl J Med. 2017 Oct5;377(14):1319-1330. PMID: 28844192
10/12/2018
19
COMPASS
~50% reduction in amputation
Eikelboom JW. N Engl J Med. 2017 Oct5;377(14):1319-1330. PMID: 28844192
Which Patients with CVD May Benefit Most?
Peripheral artery disease High risk population for MALE, CVA
Combination should replace ASA as standard of care
Timing? Voyager PAD study (immediately post re-vascularization)
High risk stable CAD? Polyvascular disease
Disease in more than one vascular bed
RIVAROXABAN 2.5 mg tabsNOT AVAILABLE YET
10/12/2018
20
DOAC for Secondary Cardiovascular Protection
55 year old with stable coronary disease with NSTEMI MI 4 years ago is on ASA 81 mg qd. His primary provider asks if he should now be started on rivaroxaban given the “new data”. You recommend:
1. Change to “low dose” rivaroxaban 5 mg bid
2. Add “very low dose” rivaroxaban 2.5 mg bid
3. Continue ASA 81 mg
ASA for VTE Prevention in High Risk Ortho Surgery
A 65 year old man with PMHx of obesity (BMI 32, weight 105 kg), HTN, OA has left total knee arthroplasty. Which is the most effective DVT prophylaxis regimen for him?
1. Rivaroxaban 10 mg QHS for 14 days2. Rivaroxaban 10 mg QHS for 5 days- ASA 81 mg daily for 2 weeks3. ASA (81 mg BID to 325 mg BID) QD for 14 days4. Honestly, who knows. But ortho wont listen to me anyway.
10/12/2018
21
Current ACCP VTE Prophylaxis Guidelines in Orthopedic Surgery
ASA vs Rivaroxaban for VTE prevention after Hip or Knee Arthroplasty
Anderson DR et al. N Engl J Med 2018
Starting on POD#6 ASA is as safe/effective as rivaroxabanFew patients with obesity cancer prior VTEPatients on higher dose ASA had higher bleed rates-use low dose ASA
10/12/2018
22
ASA for VTE Prevention in High Risk Ortho Surgery
A 65 year old man with PMHx of obesity (BMI 32, weight 105 kg), HTN, OA has left total knee arthroplasty. Which is the most effective DVT prophylaxis regimen for him?
1. Rivaroxaban 10 mg QHS for 14 days2. Rivaroxaban 10 mg QHS for 5 days- ASA 81 mg daily for 2 weeks3. ASA (81 mg BID to 325 mg BID) QD for 14 days4. Honestly, who knows. But ortho wont listen to me anyway.
Dual Therapy with DOACPost PCI in NVAF
A 68 yo man with AFIB, DM, HTN on dabigatran and metoprolol presents with NSTEMI. Cardiac cath shows 90% occlusion in left circumflex, he has PCI with drug eluting stent. You are preparing him for discharge. What antithrombotic regimen should he be discharged on?
1. Triple therapy with dabigatran, clopidigrel and ASA2. Dual therapy with dabigatran and clopidigrel3. Dual therapy with clopidigrel and ASA‐restart dabigatran
after dropping one of the antiplatelet agents4. Whatever cardiology tells me to do
10/12/2018
23
Dual Therapy with DOAC Post-PCI in NVAF
AFIB and PCI for ACS or CAD110 dabi + P2Y12 inhibitor;150 mg dabi + P2Y 12 inhibitor or triple therapy with warfarin ASA plus P2Y 12 inhibitor1◦ endpoint-major and CRNM bleeding2◦ endpoint composite of TE death or revasculization
Dual Therapy with DOAC Post-PCI in NVAF
15%
27%26%
20%
Dual therapy with dabigatran and P2Y12 inhibitor resulted in lowerrisk of bleeding with non inferior Rates of TE when compared to tripletherapy
10/12/2018
24
Piccini JP. N Engl J Med. 2017 Oct 19;377(16):1580-1582. PMID: 29045197
Dual Therapy with DOAC Post-PCI in NVAF
AFIB PCI Antithrombotic Therapy
Angiolillo et al. Circulation 2018
10/12/2018
25
AFIB PCI Antithrombotic Therapy
AFIB PCI Antithrombotic Therapy
In AF patients requiring OAC undergoing electivePCI/stenting, where bleeding risk is high (HASBLED‡ 3), we suggest triple therapy for 1 month,followed by dual therapy with OAC plus singleantiplatelet (preferably clopidogrel) for 6 months,following which OAC monotherapy can be used(Weak recommendation, low quality evidence).
10/12/2018
26
Dual Therapy with DOAC Post-PCI in NVAF
A 68 yo man with AFIB, DM, HTN on dabigatran, ASA and metoprolol presents with NSTEMI. Cardiac cath shows 90% occlusion in left circumflex, he has PCI with drug eluting stent. You are preparing him for discharge. What antithrombotic regimen should be discharged on?
1. Triple therapy with dabigatran, Plavix and ASA
2. Dual therapy with dabigatran and Plavix
3. Dual therapy with Plavix and ASA‐restart dabigatran after dropping one of the antiplatelet agents
4. Whatever cardiology tells me to do
DOAC selection, dosing, monitoring
Mr. M is an 80 year old man with CHF, HTN, CKD, and new non valvularAFIB. SCr = 1.4 mg/dL, Wt 70 kg. He has a remote history of GI bleed from gastritis. He is on a PPI. He does not want to use warfarin and is interested in a “new” blood thinner. Which DOAC do you choose for him?
52
10/12/2018
27
DOAC Selection in NVAF53Dabigatran Rivaroxaba
nApixaban Edoxaban
MOA FIIa inh FXa inh FXa inh FXa inhAdmin BID
swallow whole
QD*w/ meal*
BID QD
Renal elimination
~80% ~1/3 ~1/4 ~1/2
DrugInteractions
P-gp CYP3A4/P-gp
CYP3A4/ P-gp
P-gp
Other No pill box - - Avoid in CrCl >95 ml/minin AFIB
DOAC Selection in NVAF
*DOACs compared to warfarin; no head-to-head RCTs
54DABI RIVA APIX EDOX
FDA Approval Trial vs. WARF
RE-LY ROCKET-AF ARISTOTLE ENGAGE
Eff: CVA, SEE Superior Noninferior Superior NoninferiorSaf: Maj bleed Similar Similar Superior SuperiorICH Superior Superior Superior SuperiorGI bleed Worse Worse Similar WorseMortality Favorable Favorable Superior Favorable Bleeds in elderly subgroup≥75 yrs
Trend of more major
bleed
Trend of more CR
bleed
Less bleed
Less major,more GI bleed
10/12/2018
28
DOAC Selection in AF:PBM CFU Algorithm55
DOACS in AFIB Selection Bottom Line
Overall, DOACs perform in most aspects as good or in some cases better than warfarin *Renal function*
Avoid dabigatran in patients with significant impairment or fluctuating or borderline renal function
Avoid edoxaban in patients with very good renal function (CrCl >95 ml/min)
High bleed risk / GI bleed history or high risk –consider apixaban
Drug interactions may guide selection
10/12/2018
29
Appropriate NVAF DOAC DosingDABI RIVA APIX EDOX
Regulardosing
150 mg BID 20 mg QD 5 mg BID 60 mg QD(CrCl ≤95)
Reduced dosing
75 mg BID 15 mg QD 2.5 mg BID 30 mg QD
Indications for lowerdose:
-CrCl 15-30 ml/min-CrCl 30-50 ml/min +DDI
-CrCl 15-50 ml/min
-2 or more:-SCr ≥1.5-Wt ≤60 kg-Age ≥80 y
-CrCl 15-50 ml/min
Studied clinically
NO Not CrCl <30 ml/min
Not CrCl <25 ml/min or SCr>2.5
Not CrCl <30 ml/min
57
NOT THE SAME AS VTE DOSINGTHERE IS EITHER A DOAC “LOAD” OR LMWH LEAD IN FOR ACUTE VTE THERE IS NO RENAL ADUSTMENT FOR VTE EXCEPT EDOXABAN
DOAC selection, dosing, monitoring
Mr. M is an 80 year old man with CHF, HTN, CKD, and new AF. SCr = 1.4 mg/dL, Wt 70 kg. He has a remote history of GI bleed from gastritis. He is on a PPI. He does not want to use warfarin and is interested in a “new” blood thinner. Which DOAC do you choose for him? CHA2DS2-VASc Score = 4; high risk CrCl ~42 ml/min You recommend apixaban 5 mg BID Now what?
58
MT1
Slide 58
MT1 lisa can you discuss why you chose 5 mg rather than 2.5 mg and the data on underdosing of DOACs and clinical outcomes here? and maybe highlihgt that he MAY meet dose reduction criteria very soon and perhaps need closer monitoring?Minichiello, Tracy, 1/14/2018
Recommended